A phase I dose-finding and pharmacokinetic study of RTA 401 (CDDO) administered as a day continuous intravenous infusion in patients with relapsed or refractory leukemias or high-risk myelodysplastic syndromes
Phase of Trial: Phase I
Latest Information Update: 19 Dec 2005
At a glance
- Drugs Bardoxolone (Primary)
- Indications Leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 19 Dec 2005 New trial record.